Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.

• DOI: 10.1200/jco.2021.39.3_suppl.11
• Publication Date: 2021-01-22T19:59:19Z
• Authors: Tenna V Henriksen; Noelia Tarazona; Thomas Reinert; Juan Antonio Carb...; Derrick Renner; Shruti Sharma; Desamparados Roda; Marisol Huerta; Susana Roselló; Lene H. Iversen; Kåre Andersson Go...; Anders Husted Madsen; Per Vadgaard Ande...; Ole Thorlacius-Us...; Uffe S. Løve; Himanshu Sethi; Alexey Aleshin; Andres Cervantes; Claus Lindbjerg A...
• Keywords: Circulating tumor DNA; Adjuvant Therapy

11 Background: Timely detection of recurrence, as well identification patients at high risk recurrence after surgery and completion adjuvant therapy, are major challenges in the treatment colorectal cancer (CRC). Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for with minimal residual disease (MRD) recurrence. The objective this prospective, multicenter study was to determine whether serial postsurgical ctDNA could identify provide an assessment therapy efficacy detect relapse earlier than standard-of-care radiological imaging. Methods: cohort comprises 265 stage I-III CRC patients, to-date largest assessed ctDNA. All had resected subset 62.6% (166 /265) additionally treated ACT. Plasma samples (n = 1503) were collected various time points median follow-up 28.4 months (range: 1.2-51.0 months). Individual tumors matched germline whole-exome sequenced somatic single nucleotide variants (SNVs) identified. Personalized multiplex PCR assays designed track tumor-specific SNVs (Signatera, bespoke mPCR NGS assay) each patient’s plasma sample. Results: Postoperative status prior ACT 218 which 9.17% (20/218) identified be MRD-positive 75% (15/20) eventually relapsed. remaining 25% (5/20) that did not relapse, received In contrast, only 13.6% (27/198) MRD-negative cases relapsed (HR: 11: 95% CI: 5.7-20; p < 0.001). Longitudinal ctDNA-positive status, post-definitive 202) associated HR 36 (95% 16-81; For 155 postoperative CEA measurements compared, wherein, found significantly RFS (HR, 7.1; CI, 3.4-15; P 0.001) compared 1.2; 0.46-3.1; 0.73). Serial detected MRD up 8 (0.56 - 21.6 months) ahead radiologic relapse. Conclusion: positive markedly reduced CEA. also shows effective can curative portion patients. longitudinal setting, predicted more reliable biomarker response monitoring.